Multidisciplinary Consensus on the Nonadherence to Clinical Management of Inhaled Therapy in Spanish asthma patients

López-Viña, Antolín; Giner, Jordi; Molina, Jesús; Palicio, Javier; Plaza, Javier; Quintano, José Antonio; Quirce, Santiago; Soria, Cristina; Uréndez, Ana María; Plaza, Vicente

doi:10.1016/j.clinthera.2017.06.010

Cited by 11 publications

(10 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non-adherence to medications has been highlighted for various chronic diseases; for example, non-adherence rate in CVDs was 50% to 60% (Naderi et al, 2012), type 2 DM was 62% (Shams & Al-azri, 2019), asthma was 24% to 76% (López-Viña et al, 2017), and chronic obstructive pulmonary disease was 49.2% (Kokturk et al, 2018). The causes of non-adherence to prescribed medication is often multifactorial and complex.…”

Section: Introductionmentioning

confidence: 99%

Medication Adherence and Patients’ Characteristics in Chronic Diseases: A National Multi-Center Study

et al. 2021

View full text Add to dashboard Cite

Chronic diseases constitute a significant threat to health. Worldwide, medication adherence in chronic diseases remains unsatisfactory. Understanding factors affecting adherence is essential. This study examined medication adherence by characteristics of patients with chronic diseases. This cross-sectional study included 800 patients. The Adherence to Chronic Diseases Scale was used to measure adherence. Descriptive statistics and logistic regression was used to examine factors influencing medication adherence. Low adherence was found in 19.5% of the patients, 45% had medium adherence, and 35.5% had high adherence. Logistic regression showed that retired ( OR 0.496, 95% CI [0.33–0.75]), having COPD ( OR 0.460, 95% CI [0.32–0.67]) and duration of disease ≤5 years ( OR 1.554, 95% CI [1.11–2.17]) remain independent predictors for high adherence. Mixed findings regarding the relationship between medication adherence and patients’ characteristics were noticed. Patients’ characteristics should be examined with the individual population when examining and attempting to improve medication adherence in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Medication Adherence and Patients’ Characteristics in Chronic Diseases: A National Multi-Center Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…• Patient compliance to drug treatments: in an everyday clinical practice, asthmatic patients are not thought to be fully compliant with their medication. Therefore, PDC was modified to 80% of days covered (average compliance treatment observed in the SLS asthma study), and 50% and 33% (based on literature [22,23]) to analyse the impact of different compliance rates on the results.…”

Section: Sensitivity Analysesmentioning

confidence: 99%

Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objectives The Salford Lung Study in asthma (SLS asthma) is a 12-month, open-label randomised clinical trial comparing clinical effectiveness of initiating once-daily inhaled combination of fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg, with continuing optimized usual care (UC) with inhaled corticosteroids (ICS) alone, or in combination with a long-acting β2-agonist (ICS/LABA), in asthmatic patients followed in primary care in the UK. The objective of the analysis is to estimate the economic impact of these results when applied in Spain. Methods A 1-year cost-consequence model was populated with SLS asthma, adopting the Spanish National Health System (NHS) perspective. 775,900 of diagnosed asthmatic patients ≥ 18 years old currently managed with UC in Spain were included in the analysis. Effectiveness data included the percentage of patients per Asthma Control Test (ACT) category at 24 and 52 weeks from SLS asthma. Direct costs (pharmacological and per ACT category) were estimated from Spanish public sources and literature (€, 2018). Base case analysis assumed an increased use of FF/VI from 10 to 20% within 1 year. One-way sensitivity analyses were performed. Results Within the 775,900 asthmatic patients analysed, substitution of UC with FF/VI was associated with reduced costs due to ACT improvement, leading to potential total annual savings of €4,927,672. Sensitivity analyses ranged from €6,012,975 to €14,783,015 cost savings associated with FF/VI. An analysis considering patients only on ICS/LABA showed potential cost savings of €8,207,448. Conclusions The improved asthma control for FF/VI compared with UC observed in SLS asthma could be translated into potential savings for the Spanish NHS. These results may be useful for decision makers.

show abstract

“…The issue is important, since low adherence has been associated with poor disease control, higher morbidity, increased number of hospitalizations, and higher mortality rate (22,23). Many strategies can be implemented to increase medication adherence, for example education programs, audiovisual feedback, electronic reminders, and increasing the number of patient-physician encounters (24)(25)(26)(27). Evidence suggests that educational intervention are perhaps the namic models are required (8,9).…”

Section: Medication Adherencementioning

confidence: 99%

Dispositivos de inhalación para asma y EPOC: una revisión de la literatura

Rincon-Montaña¹,

Rosselli²

2019

rev. colomb. neumol.

View full text Add to dashboard Cite

Las investigaciones recientes se han concentrado en el desarrollo de nuevos dispositivos de inhalación. La innovación ha mejorado los inhaladores de dosis medida, polvo seco o res- piración controlada y los nebulizadores. El objetivo de este estudio fue realizar una revisión narrativa de la literatura acerca de los diferentes dispositivos de inhalación que se encuen- tran disponibles en el mercado y su asociación con los desenlaces para asma y EPOC. Las principales preocupaciones han sido facilitar la administración del medicamento al paciente favoreciendo la farmacocinética, seguridad, preferencia del paciente, cumplimiento de la medicación, calidad de vida y costos. La adherencia a la medicación tiene una asociación po- sitiva con la preferencia del paciente y la facilidad de uso del dispositivo que administra los medicamentos para el control de la enfermedad. Una buena adherencia a los medicamentos puede reducir los episodios de exacerbación, mejorar la calidad de vida y reducir los costos de las enfermedades respiratorias.

show abstract

Multidisciplinary Consensus on the Nonadherence to Clinical Management of Inhaled Therapy in Spanish asthma patients

Cited by 11 publications

References 24 publications

Medication Adherence and Patients’ Characteristics in Chronic Diseases: A National Multi-Center Study

Medication Adherence and Patients’ Characteristics in Chronic Diseases: A National Multi-Center Study

Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

Dispositivos de inhalación para asma y EPOC: una revisión de la literatura

Contact Info

Product

Resources

About